NVS R&D Expenses

Novartis AG Common Stock · R&D Expenses

NVS logo

NVS R&D Expenses

Latest reported$11.28B
NVS R&D Expenses ($2.84B → $11.28B)
High-resolution chart · PNG

NVS r&d expenses history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
10,741,727,000
10,022,000,000
11,371,000,000
9,172,000,000
8,641,000,000
8,980,000,000
9,402,000,000
8,489,000,000
8,389,000,000
9,039,000,000
8,935,000,000
9,086,000,000
9,071,000,000
8,588,000,000
9,583,000,000
9,070,000,000
7,469,000,000
7,217,000,000
6,430,000,000
5,321,000,000
4,797,000,000
4,152,000,000
3,729,000,000
2,843,000,000
2,528,000,000
2,885,000,000
2,666,000,000
2,838,663,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.